US Patent 10406213 Injection paradigm for administration of botulinum toxins
Patent 10406213 was granted and assigned to Allergan, Inc. on September, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+376 characters)
Article
Patent abstract
Methods for treating a patient suffering from a medication overuse headache disorder are provided. The methods comprise administering to a patient suffering from a medication overuse disorder a Clostridial toxin. The toxin is administered to the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Catherine C. Turkel0
Mitchell F. Brin0
Sheena K. Aurora0
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 6 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 28 Mar, 2023
Golden AI
Infobox
Edits on 27 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 25 Sep, 2022
Golden AI
Infobox
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 12 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 28 Jan, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
US Patent 10406213 Injection paradigm for administration of botulinum toxins
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10406213
Date of patent
September 10, 2019
Patent application number
15707452
Date Filed
September 18, 2017
Patent citations
Patent primary examiner
Find more entities like US Patent 10406213 Injection paradigm for administration of botulinum toxins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
